A Phase 1/2 Study of SCH727965 in Patients With Malignant Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Dinaciclib (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic; Therapeutic Use
- 22 Jun 2016 Status changed from active, no longer recruiting to discontinued.
- 21 Feb 2013 Planned end date changed from 1 Aug 2010 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 21 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.